The Improvement Of Menu Based On Pare As A Diet Menu Specially In Diabetes Mellitus Patients In Hospitals

2020 ◽  
Vol 2 (1) ◽  
pp. 32-37
Author(s):  
Praseptia Gardiarini ◽  
Ria Setyawati
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bitter Taste ◽  
Lifestyle Changes ◽  
Bitter Melon ◽  
Diabetic Mellitus ◽  
Menu Item ◽  
Long Time ◽  
Selection Of

Background: Diabetes Mellitus (DM) is a disease whose prevalence has increased every year. The increase in prevalence is thought to be due to lifestyle changes and urbanization that affect the pattern and selection of food menus. One of the easiest management is to consume drugs, but the use of repentance for a long time will cause side effects and quite expensive costs.Pare is one type of vegetable that can be used as an alternative to the main food menu for diabetic mellitus, but because the taste is bitter, Pare is rarely used as a daily menu. Even at the Hospital a Pare-based menu is rarely applied to patients, especially those with Diabetes. Object: This study aims to examine the development of Pare-based menus so that it can be used as an alternative menu for inpatients in hospitals, especially for people with Diabetes Mellitus. Methods:There are two methods used in this study, experimental research methods and statistical descriptions. Result: The results of the stir-fried bitter melon from the experiment were bitter melon vegetables whose color was fresh green, the distinctive aroma of bitter melon still smelled, the texture was soft and the bitter taste was somewhat reduced. Panelist's hedonic test, who stated that they rather like 6 (18.8%), and like 21 (65.6%) and really like 4 (12.5%). Conclsion: Based on the results of the study, it can be concluded that bitter melon can be a basic menu item for type 2 diabetes mellitus patients hospitalized at the hospital.

FAMILY DIABETES AND MAIN NONCOMMUNICABLE DISEASES: THE DESCRIBED AND POTENTIAL EFFECT OF METFORMIN (remembering Vladimir Dilman)

2020 ◽  
pp. 713-720
Author(s):  
Л. М. Берштейн
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Potential Effect ◽  
Noncommunicable Diseases ◽  
The Family ◽  
Whole Number ◽  
Long Time ◽  
Relationship Of ◽  
Antidiabetic Biguanides

Работа посвящена двум медико-биологическим проблемам - семейному диабету (имея в виду наличие случаев сахарного диабета 2-го типа в семье, в том числе в разных поколениях), а также особенностям его связей с основными неинфекционными заболеваниями человека и приурочена к юбилею известнейшего отечественного специалиста (теоретика и врача) в области геронтологии и эндокринологии профессора В. М. Дильмана. Широко признанные труды Владимира Михайловича, основанные на оригинальных идеях и породившие важные практические следствия (включая применение антидиабетических бигуанидов в не использовавшихся до него областях, необходимость устранения метаболической иммунодепрессии, учета изменений с возрастом на уровне гипоталамического порога в различных гомеостатических системах и целого ряда других предложений), как представляется, в течение долгого времени будут питать интеллектуальным материалом и стимулировать к дальнейшему поиску его последователей и специалистов, которым еще предстоит окунуться в область, очерченную В. М. Дильманом и интересовавшую его в течение многих лет. The work discusses the two biomedical problems: family diabetes (bearing in mind the presence of cases of type 2 diabetes mellitus in the family, including its different generations) and the features of relationship of family diabetes with major non-communicable human diseases (NCDs). The paper is timed to the anniversary of the famous - in our country and abroad - expert in the field of gerontology and endocrinology, Professor V. M. Dilman. The widely recognized works of V. M. Dilman, based on original ideas and giving rise to important practical consequences (including the use of antidiabetic biguanides in areas not studied before him, the need to eliminate metabolic immunodepression, to take into account the changes with age at the level of the hypothalamic threshold in various homeostatic systems and a whole number of other essential proposals), which for a long time, as it seems, will stimulate the further scientific search of his followers and specialists, who have yet to get acquainted with the area that attracted Prof. Dilman and interested him for many years.

scholarly journals Prevalence of Diabetic Retinopathy in Type 1 and Type 2 Diabetes Mellitus Patients in North-East Poland

Medicina ◽  
2020 ◽  
Vol 56 (4) ◽  
pp. 164
Author(s):  
Wojciech Matuszewski ◽  
Angelika Baranowska-Jurkun ◽  
Magdalena M. Stefanowicz-Rutkowska ◽  
Robert Modzelewski ◽  
Janusz Pieczyński ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Retinopathy ◽  
Proliferative Diabetic Retinopathy ◽  
Lifestyle Changes ◽  
North East ◽  
Experimental Group

Background and Objectives: The global epidemic of diabetes, especially type 2 (DM2), is related to lifestyle changes, obesity, and the process of population aging. Diabetic retinopathy (DR) is the most serious complication of the eye caused by diabetes. The aim of this research was to assess the prevalence of diabetic retinopathy in type 1 and type 2 diabetes mellitus patients in north-east Poland. Materials and Methods: The eye fundus was assessed on the basis of two-field 50 degrees color fundus photographs that showed the optic nerve and macula in the center after the pupil was dilated with 1% tropicamide. Results: The experimental group included 315 (26%) patients with type 1 diabetes mellitus (DM1) and 894 (74%) patients with DM2. DM1 patients were diagnosed with DR in 32.58% of cases, with non-proliferative diabetic retinopathy (NPDR) in 24.44% of cases, proliferative diabetic retinopathy (PDR) in 1.59% of cases, diabetic macular edema (DME) in 5.40% of cases, and PDR with DME in 0.95% of cases. DR was found in DM2 patients in 23.04% of cases, NPDR in 17.11% of cases, PDR in 1.01% of cases, DME in 4.81% of cases, and PDR with DME in 0.11% of cases. Conclusions: The presented study is the first Polish study on the prevalence of diabetic retinopathy presenting a large group of patients, and its results could be extrapolated to the whole country. Diabetic retinopathy was found in 25.48% of patients in the whole experimental group. The above results place Poland within the European average, indicating the quality of diabetic care offered in Poland, based on the number of observed complications.

scholarly journals THE WAY TO PREDICT THE EFFECTIVENESS OF BARIATRIC SURGERY IN PATIENTS WITH COMORBID OBESITY IN POST-PANDEMIC PERIOD

2020 ◽  
pp. 91-94
Author(s):  
M. I. Marushchak ◽  
I. Ya. Krynytska ◽  
I. Ya. Dzyubanovskyі
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bariatric Surgery ◽  
Type 2 Diabetes Mellitus ◽  
Arterial Hypertension ◽  
Lifestyle Changes ◽  
Atherogenic Dyslipidemia ◽  
Short Term ◽  
Treatment Of Obesity

Summary. It is estimated that from 650 million to 2 billion adults worldwide, are overweight or obese, the numbers indicating epidemic levels of disease. In individuals, body mass index (BMI) exceeding 27 kg/m2 is associated with a high risk of mortality and the presence of comorbid pathologies, in particular, atherogenic  dyslipidemia, arterial hypertension (AH), type 2 diabetes mellitus (T2D), thromboembolism, hepatic steatosis, etc. Preliminary data indicate that obesity is among key risk factors in severe and fatal cases of COVID-19, when comorbid with AH and T2D. The aim of this study – to analyze the possibility of developing an optimized model utilizing anamnestic, clinical, biochemical and genetic parameters for predicting the outcomes of bariatric surgery in the patients with obesity, type 2 diabetes mellitus (T2D) and/or arterial hypertension (AH). Results. Lifestyle changes and conservative treatment of obesity usually only result in a short-term effect, since the measures aiming to induce weight loss consign the person to a constant struggle with natural homeostatic processes. Recurrence of obesity in such patients is observed in 95 % of the cases. Therefore, the International Association of Endocrinologists recommends that patients with a BMI greater than 40 kg/m2, as well as with a BMI of 35.0 to 39.9 kg/m2 and metabolic syndrome undergo a surgical treatment of obesity using minimally invasive techniques. At the same time, a number of issues associated with bariatric laparoscopic interventions remain unresolved, since these procedures are invasive and carry all the risks accompanying surgery, general  anesthesia, and the postoperative recovery period. An  innovative surgical approach, the X-ray endovascular bariatric embolization of the gastric arteries (BAE) is proposed as an alternative to laparoscopic intervention. However, the indications for the use of BAE are undefined, especially in the cases of comorbid obesity; there are no clear algorithms and guidelines for its use. Conclusions. There have been no comprehensive studies of short-term, intermediate and long-term outcomes of BEA in Ukraine. This warrants the need to develop an optimal model for predicting the outcomes of both classical bariatric laparoscopic surgery with regulated gastric band and innovative BEA procedure in patients with comorbid obesity in post-pandemic period  using anamnestic, clinical, biochemical and genetic predictors.

scholarly journals Current Management of Type 2 Diabetes Mellitus: What to Pay Attention to in Outpatient Settings

Doctor Ru ◽  
2021 ◽  
Vol 20 (2) ◽  
pp. 40-44
Author(s):  
N.A. Chernikova ◽  
◽  
O.A. Knyshenko ◽  
◽  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combined Therapy ◽  
Individual Characteristics ◽  
Antihyperglycemic Agents ◽  
Number Of Patients ◽  
Antihyperglycemic Therapy ◽  
Selection Of

Objective of the Review: To discuss the problem of selecting antihyperglycemic drugs; to identify the trends in prescription of various groups of oral antihyperglycemic agents. Key Points. When type 2 diabetes mellitus (DM2) is diagnosed, a number of patients need prompt combined antihyperglycemic therapy because of a marked carbohydrate metabolism disorder. The prescription paradigm of initial therapy has shifted towards antihyperglycemic agents with established nephro- and cardioprotective effects (sodium-glucose linked transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists). Drugs are recommended depending on presence or absence of a comorbid cardiovascular disease (CVD) and cardiovascular risk factors, and safety as regards hypoglycaemic events; therefore, very often selection of a therapeutic regimen can be challenging. Still, the first-line treatment for patients without CVD is metformin; however, a combined therapy is required in the majority of cases. Poor compliance, continued use of monotherapy, despite the need to boost the therapy, patient’s reluctance to take additional drugs can facilitate occurrence and progression of a lot of associated complications. In such cases, combined medications reducing the amount of tablets and improving compliance are useful. The most common combination of antihyperglycemic drugs is metformin and sulfonylureas. Still, care should be taken because of differences in pharmacokinetics and pharmacodynamics of the molecules in the latter group. High selectivity of some sulfonylureas can evidence their milder effect for glucose level reduction. Sulfonylureas are also cost-effective as compared to other antidiabetic medications. Conclusion. A wide choice of drugs allows a medical professional selecting an optimal antihyperglycemic regimen, taking into account individual characteristics of a patient. Prompt combined medications are a treatment of choice for the majority of patients with DM. Selection of antihyperglycemic drugs is affected by the cost as well. The most important thing is that the drugs are well-studied, efficient and safe. Keywords: type 2 diabetes mellitus, combined therapy, sulphonylurea, Glimepiride, metformin.

scholarly journals Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association

Circulation ◽  
2020 ◽  
Vol 141 (19) ◽  
Author(s):  
Suzanne V. Arnold ◽  
Deepak L. Bhatt ◽  
Gregory W. Barsness ◽  
Alexis L. Beatty ◽  
Prakash C. Deedwania ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Type 2 Diabetes Mellitus ◽  
Coronary Artery ◽  
Cardiovascular Outcomes ◽  
Artery Disease ◽  
Selection Of

Although cardiologists have long treated patients with coronary artery disease (CAD) and concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a comorbidity that affected the development and progression of the disease. Over the past decade, a number of factors have shifted that have forced the cardiology community to reconsider the role of T2DM in CAD. First, in addition to being associated with increased cardiovascular risk, T2DM has the potential to affect a number of treatment choices for CAD. In this document, we discuss the role that T2DM has in the selection of testing for CAD, in medical management (both secondary prevention strategies and treatment of stable angina), and in the selection of revascularization strategy. Second, although glycemic control has been recommended as a part of comprehensive risk factor management in patients with CAD, there is mounting evidence that the mechanism by which glucose is managed can have a substantial impact on cardiovascular outcomes. In this document, we discuss the role of glycemic management (both in intensity of control and choice of medications) in cardiovascular outcomes. It is becoming clear that the cardiologist needs both to consider T2DM in cardiovascular treatment decisions and potentially to help guide the selection of glucose-lowering medications. Our statement provides a comprehensive summary of effective, patient-centered management of CAD in patients with T2DM, with emphasis on the emerging evidence. Given the increasing prevalence of T2DM and the accumulating evidence of the need to consider T2DM in treatment decisions, this knowledge will become ever more important to optimize our patients’ cardiovascular outcomes.

scholarly journals Lifestyle changes in patients with morbid obesity and type 2 diabetes mellitus during the COVID-19 pandemic

2020 ◽  
Author(s):  
Michał Wysocki ◽  
Maciej Walędziak ◽  
Monika Proczko-Stepaniak ◽  
Michał Pędziwiatr ◽  
Jacek Szeliga ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Morbid Obesity ◽  
Type 2 Diabetes Mellitus ◽  
Lifestyle Changes
Sign in / Sign up

Export Citation Format

Share Document